NASDAQ:XFORX4 Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding X4 Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.89 0.00 (0.00 %) (As of 06/3/2020 04:00 PM ET) Add Compare Share Today's Range$8.80Now: $8.89▼$9.0550-Day Range$8.54MA: $9.12▼$9.9052-Week Range$5.84Now: $8.89▼$17.38Volume77,542 shsAverage Volume71,702 shsMarket Capitalization$143.50 millionP/E RatioN/ADividend YieldN/ABeta0.47 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingX4 Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.67, X4 Pharmaceuticals has a potential upside of 121.2% from its current price of $8.89.Amount of Analyst CoverageX4 Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.7 Community Rank Outperform VotesX4 Pharmaceuticals has received 48 “outperform” votes. (Add your “outperform” vote.)Underperform VotesX4 Pharmaceuticals has received 40 “underperform” votes. (Add your “underperform” vote.)Community SentimentX4 Pharmaceuticals has received 54.55% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about X4 Pharmaceuticals and other stocks. Vote “Outperform” if you believe XFOR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe XFOR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldX4 Pharmaceuticals does not currently pay a dividend.Dividend GrowthX4 Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, X4 Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $164,659.00 in company stock.Percentage Held by InsidersOnly 3.80% of the stock of X4 Pharmaceuticals is held by insiders.Percentage Held by Institutions69.78% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for X4 Pharmaceuticals are expected to grow in the coming year, from ($2.73) to ($2.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of X4 Pharmaceuticals is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of X4 Pharmaceuticals is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioX4 Pharmaceuticals has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.89 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XFOR Previous Symbol CUSIPN/A CIKN/A Webwww.x4pharma.com Phone857-529-8300Debt Debt-to-Equity Ratio0.23 Current Ratio15.34 Quick Ratio15.34Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.37 per share Price / Book0.86Profitability EPS (Most Recent Fiscal Year)($4.63) Net Income$-52,810,000.00 Net MarginsN/A Return on Equity-46.37% Return on Assets-35.21%Miscellaneous Employees63 Outstanding Shares16,142,000Market Cap$143.50 million Next Earnings Date8/4/2020 (Estimated) OptionableNot Optionable NASDAQ:XFOR Rates by TradingView Receive XFOR News and Ratings via Email Sign-up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter. X4 Pharmaceuticals (NASDAQ:XFOR) Frequently Asked Questions How has X4 Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? X4 Pharmaceuticals' stock was trading at $8.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, XFOR shares have increased by 3.6% and is now trading at $8.89. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of X4 Pharmaceuticals? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for X4 Pharmaceuticals. When is X4 Pharmaceuticals' next earnings date? X4 Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for X4 Pharmaceuticals. How were X4 Pharmaceuticals' earnings last quarter? X4 Pharmaceuticals Inc (NASDAQ:XFOR) issued its quarterly earnings results on Thursday, May, 7th. The company reported ($0.56) EPS for the quarter, topping the Zacks' consensus estimate of ($0.83) by $0.27. The company had revenue of $3 million for the quarter. View X4 Pharmaceuticals' earnings history. What price target have analysts set for XFOR? 8 analysts have issued 12 month target prices for X4 Pharmaceuticals' shares. Their forecasts range from $15.00 to $27.00. On average, they anticipate X4 Pharmaceuticals' stock price to reach $19.67 in the next twelve months. This suggests a possible upside of 121.2% from the stock's current price. View analysts' price targets for X4 Pharmaceuticals. Has X4 Pharmaceuticals been receiving favorable news coverage? Media stories about XFOR stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. X4 Pharmaceuticals earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutX4 Pharmaceuticals. Who are some of X4 Pharmaceuticals' key competitors? Some companies that are related to X4 Pharmaceuticals include MeiraGTx (MGTX), DBV TECHNOLOGIE/S (DBVT), Rubius Therapeutics (RUBY), Scholar Rock (SRRK), Innate Pharma (IPHYF), Autolus Therapeutics (AUTL), Voyager Therapeutics (VYGR), Harpoon Therapeutics (HARP), Precision BioSciences (DTIL), PDL BioPharma (PDLI), Eiger Biopharmaceuticals (EIGR), Verona Pharma (TARA), CASI Pharmaceuticals (CASI), ADMA Biologics (ADMA) and Cellular Biomedicine Group (CBMG). View all competitors. What other stocks do shareholders of X4 Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Crispr Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), Selecta Biosciences (SELB), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Albireo Pharma (ALBO), Alnylam Pharmaceuticals (ALNY) and Axsome Therapeutics (AXSM). Who are X4 Pharmaceuticals' key executives? X4 Pharmaceuticals' management team includes the following people: Dr. Paula Ragan, Founder, CEO, Pres, Sec. & Director (Age 50)Dr. Renato T. Skerlj, Founder, Sr. VP of R&D and Member of Scientific Advisory BoardMr. Adam S. Mostafa, CFO, Treasurer & Assistant Sec. (Age 40)Dr. Mary DiBiase, Sr. VP of Technical Operations & QualityMr. Derek M. Meisner Esq., J.D., Gen. Counsel (Age 49) What is X4 Pharmaceuticals' stock symbol? X4 Pharmaceuticals trades on the NASDAQ under the ticker symbol "XFOR." Who are X4 Pharmaceuticals' major shareholders? X4 Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.43%), Sphera Funds Management LTD. (5.41%), RA Capital Management L.P. (3.73%), AXA (3.11%), Cormorant Asset Management LP (2.12%) and State Street Corp (1.70%). View institutional ownership trends for X4 Pharmaceuticals. Which institutional investors are selling X4 Pharmaceuticals stock? XFOR stock was sold by a variety of institutional investors in the last quarter, including Bleichroeder LP, Morgan Stanley, New York State Common Retirement Fund, UBS Group AG, ClariVest Asset Management LLC, and Deutsche Bank AG. View insider buying and selling activity for X4 Pharmaceuticals. Which institutional investors are buying X4 Pharmaceuticals stock? XFOR stock was purchased by a variety of institutional investors in the last quarter, including AXA, RA Capital Management L.P., Sphera Funds Management LTD., State Street Corp, Cormorant Asset Management LP, BlackRock Inc., Geode Capital Management LLC, and Nuveen Asset Management LLC. View insider buying and selling activity for X4 Pharmaceuticals. How do I buy shares of X4 Pharmaceuticals? Shares of XFOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is X4 Pharmaceuticals' stock price today? One share of XFOR stock can currently be purchased for approximately $8.89. How big of a company is X4 Pharmaceuticals? X4 Pharmaceuticals has a market capitalization of $143.50 million. The company earns $-52,810,000.00 in net income (profit) each year or ($4.63) on an earnings per share basis. X4 Pharmaceuticals employs 63 workers across the globe. What is X4 Pharmaceuticals' official website? The official website for X4 Pharmaceuticals is www.x4pharma.com. How can I contact X4 Pharmaceuticals? X4 Pharmaceuticals' mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-529-8300 or via email at [email protected] This page was last updated on 6/4/2020 by MarketBeat.com Staff
